Integrin antagonists

A compound of the formula:

• or a pharmaceutically acceptable salt or tautomer thereof,
• wherein:
• R1 is hydrogen, unsubstituted C1-8alkyl, substituted C1-8alkyl;
• R2 is hydrogen, unsubstituted C1-8alkyl, or substituted C1-8alkyl;
• X is hydrogen, halo, cyano, unsubstituted C1-12alkyl, substituted C1-12alkyl, unsubstituted C1-12alkoxy, substituted C1-12alkoxy, unsubstituted 3-10 membered heterocycloalkyl, substituted 3-10 membered heterocycloalkyl, unsubstituted C2-12acyloxy, substituted C2-12acyloxy, or
• where R4 and R5 are each independently unsubstituted C1-8alkyl or substituted C1-8alkyl, and
• R6 is hydrogen, —OH, —CN, —NH2, —CF3, —CF2H, —CH2F, —CO2H, —CO2—C1-8alkyl, —C(═O)NH2, —CH2OH, —CH2O—C1-8alkyl, or C1-8alkoxy, or
• X is
• where A′ is —CF2—, —O—, C1-6alkanediyl, C1-8alkoxydiyl, or a covalent bond, thereby forming a cyclopropane ring, and
• R7 is —OH, —CN, —NH2, —CO2H, —CO2—C1-8alkyl, —C(═O)NH2, —CF3, —CF2H, —CH2F, —CH2OH, —CH2O—C1-8alkyl, C1-8alkyl or C1-8alkoxy;
• Y is t-butyl, or
• where R8 and R9 are each independently unsubstituted C1-8alkyl or substituted C1-8alkyl,
• and R10 is hydrogen, —OH, —CN, —NH2, —CF3, —CF2H, —CFH2, —CO2H, —CO2—C1-8alkyl, —C(═O)NH2, —CH2OH, CH2O—C1-8alkyl, or C1-8alkoxy, or
• Y is
• where A″ is —CF2—, —O—, C1-6alkanediyl, C1-8alkoxydiyl, or a covalent bond, thereby forming a cyclopropane ring;
• and R11 is —OH, —CN, —NH2, —CO2H, —CO2—C1-8alkyl, —C(═O)NH2, —CF3, —CF2H, —CH2F, —CH2OH, —CH2O—C1-8alkyl, C1-8alkyl or C1-8alkoxy.